Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd demonstrates a strong positive outlook due to its innovative rhCollagen-based product, Collink.3D, which has shown superior performance in supporting structured tissue formation compared to traditional animal-derived matrices and is gaining scientific validation as a sustainable alternative for tissue engineering. The operationalization of a U.S.-based logistics center is expected to enhance sales prospects for both BioInk and rhCollagen, driven by increasing adoption rates among research institutions and tissue-engineering customers. Additionally, strategic partnerships, particularly with Allergan, and ongoing developments in the photocurable dermal filler program are likely to create significant revenue catalysts and strengthen the company's market position in regenerative medicine and medical aesthetics.

Bears say

CollPlant Biotechnologies Ltd's recent $2.0 million registered direct financing at a price of $1.25 per share highlights ongoing pressure on the company's equity, suggesting limited capacity for capital formation amid a challenging financial environment. The decision to reduce expectations for key products, including Dermal Fillers and BioInk, as well as the removal of Breast Implants from financial forecasts, indicates potential challenges in product development and market penetration. This combination of factors may undermine investor confidence and contribute to a downward valuation trend for the company.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.